Koninklijke Philips (PHIA) Q2 2024 earnings summary

Executive summary

• Q2 2024 delivered 2% comparable sales growth to EUR 4.5 billion, with a 9% increase in order intake and margin improvement across all businesses, despite a challenging macro environment.

• All business segments contributed to growth, supported by productivity programs, innovation launches, and enhanced patient safety and supply chain reliability.

• Net income reached EUR 452 million, significantly up from EUR 74 million in Q2 2023, mainly due to EUR 538 million insurance income related to Respironics product liability claims.

• S&P and Moody’s upgraded credit rating outlook to stable.

• Reiterated full-year 2024 outlook, expecting continued performance improvement, supported by innovation and execution priorities.

Financial highlights

• Q2 comparable sales grew 2% year-over-year to EUR 4,462 million, with Diagnosis & Treatment up 4%, Connected Care and Personal Health both up 2%.

• Adjusted EBITA/EBITDA margin improved to 11.1% (EUR 495 million), up from 10.1% in Q2 2023; segment margin rose to 12.2%.

• Free cash outflow of EUR 64 million, impacted by a EUR 415 million settlement payment, partially offset by EUR 150 million insurance receipt.

• EPS from continuing operations (diluted) was EUR 0.33, up from EUR 0.07 in Q2 2023; adjusted EPS was EUR 0.30.

• Gross margin improved to 44.6% from 43.9% in Q2 2023.

Outlook and guidance

• Expects 3%-5% comparable sales growth for 2024, with adjusted EBITA/EBITDA margin of 11%-11.5% and free cash flow of EUR 0.9-1.1 billion.

• All business segments expected within the 3%-5% sales growth range; Connected Care at upper end, Diagnosis & Treatment and Personal Health at lower end.

• Guidance excludes potential impact of ongoing Respironics-related legal proceedings.